Frontier Pharma: Prostate Cancer Market Quantitative Analysis - PowerPoint PPT Presentation

View by Category
About This Presentation

Frontier Pharma: Prostate Cancer Market Quantitative Analysis


The report analyzes innovation in prostate cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzed the deals landscape surrounding first-in-class products in prostate cancer, and pinpoints opportunities for in-licensing. For Further Details : – PowerPoint PPT presentation

Number of Views:54


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Frontier Pharma: Prostate Cancer Market Quantitative Analysis

Frontier Pharma Prostate Cancer - Identifying
and Commercializing First-in-Class Innovation
Exceptionally Large and Innovative Pipeline The
prostate cancer pipeline is among the largest in
the pharmaceutical industry with 484 products in
active development across all stages. The range
of mechanisms of action employed by these
compounds is also highly diverse, especially in
comparison to the existing market landscape.
More pertinently, the degree and proportion of
breakthrough innovations in this pipeline is
exceptional GBI Research analysis identified 174
first-in-class programs in the prostate cancer
pipeline, acting on 122 first-in-class molecular
targets. This accounts for some 36 of all
products with a disclosed molecular target and is
reflective of the high degree of innovation in
this indication. This has far-reaching strategic
implications for all market participants, as,
despite the high attrition rate in prostate
cancer, it is highly likely many of the
first-in-class technologies will reach the market
over the coming decade and may transform the
clinical and commercial landscape. For Further
Details http//
Report Description
  • Alignment of First-in-Class Molecular Target with
    Disease Causation
  • One of the key trends in oncology and in prostate
    cancer in particular over the last decade is the
    clinical and commercial impact of targeted
    therapies designed to target proteins in
    signaling pathways that are strongly associated
    with disease progression.
  • By aligning the molecular targets for
    therapeutic intervention with disease causation
    and/or propagation, these therapies limit the
    systemic cytotoxic effects whilst inhibiting
    tumor-promoting signaling pathways. Such
    strategies thereby typically achieve superior
    efficacy and safety profiles.
  • Our proprietary analyses demonstrate significant
    levels of differentiation as to how well the
    first-in-class products and their respective
    molecular targets align to underlying gene and
    protein level mutations and dysfunction.

Report Description
  • More advanced analytics further substantiated
    these findings as strong levels of
    differentiation in the scientific and clinical
    rationale for first-in-class molecular targets
    emerged. Furthermore, clear frontrunners were
    identified by integrating analyses to assess the
    accessibility of molecular targets for
    therapeutic compounds, the size of the target
    patient population that would benefit from
    therapeutic intervention, and the expected
    positioning of the first-in-class products based
    on the molecular targets and mechanisms of action
    of currently marketed products .
  • These insights and a detailed review of the
    available evidence from scientific studies
    substantiate the perspective that
    first-in-class-product technology in its own
    right is not sufficient to offer a compelling
    scientific and clinical rationale. However, a
    range of products offer very significant
    scientific and clinical promise and could
    therefore result in a strong commercial
    proposition with the prospect of clinically and
    commercially transformative products in the
  • Read The Complete Report On http//www.bigmarket

Key Market
  • A Deals Landscape with Numerous Investment
  • Analysis has confirmed that 169 of the 174
    first-in-class products have not been involved in
    a licensing or co-development deal. Although many
    act on targets that are not yet strongly
    substantiated in terms of their therapeutic
    potential in prostate cancer in clinical studies,
    there are many which are supported by promising
    in vivo and in vitro preclinical evidence, and as
    such are highly promising prostate cancer
    therapies. Indeed, breakthrough innovations are
    highly desirable as an investment option.
  • However, most deals involving first-in-class
    products were either preclinical or Phase I
    development, whereas advance-in-class and
    addition-to-class product deals were typically
    made in Phases II and III, therefore showing
    significant differentiation. These findings have
    significant strategic implications for both
    biotech companies seeking to out-license products
    and firms with an interest in in-licensing
    first-in-class products with strong clinical and
    commercial prospects.

  • The report analyzes innovation in prostate
    cancer, in the context of the overall pipeline
    and current market landscape. In addition, it
    analyzed the deals landscape surrounding
    first-in-class products in prostate cancer, and
    pinpoints opportunities for in-licensing. The
    report covers and includes
  • A brief introduction to prostate cancer,
    including symptoms, pathophysiology, and overview
    of pharmacotherapy and treatment algorithms.
  • The changing molecular target landscape between
    market and pipeline and particular focal points
    of innovation in the pipeline.
  • Comprehensive review of the pipeline for
    first-in-class therapies, analyzed on the basis
    of stage of development, molecule type and
    molecular target.
  • Identification and assessment of first-in-class
    molecular targets with a particular focus on
    early-stage programs of which clinical utility
    has yet to be evaluated, as well as literature
    reviews on novel molecular targets.
  • Assessment of the licensing and co-development
    deal landscape for prostate cancer therapies and
    benchmarking of deals involving first-in-class
    versus non-first-in-class-products.

Reasons to buy
  • The report will assist business development and
    enable marketing executives to strategize their
    product launches, by allowing them to
  • Understanding of the focal shifts in molecular
    targets in the prostate cancer pipeline.
  • Understanding of the distribution of pipeline
    programs by phase of development, molecule type
    and molecular target.
  • Access a scientific and clinical analysis of
    first-in-class developmental programs for
    prostate cancer, benchmarked against
    non-first-in-class targets.
  • Access a list of the first-in-class therapies
    potentially open to deal-making opportunities
  • To get More Details Enquire _at_

Table Of Content
  • Executive Summary
  • The Case for Innovation in Prostate Cancer
  • Clinical and Commercial Landscape
  • Assessment of Pipeline Product Innovation
  • Signaling Network, Disease Causation and
    Innovation Alignment
  • First-in-Class Target and Pipeline Program
  • Pipeline Programs Targeting Aurora Kinase
  • Deals and Strategic Consolidations
  • Appendix
  • Read The Complete TOC _at_ http//www.bigmarketresear

Contact Us
Deep Joshi 5933 NE Win Sivers Drive, 205,
Portland, OR 97220 United States Direct 1
(617) 674-4143 Toll Free 1 (855) 711-1555 Fax
1 (855) 550-5975 Email help_at_bigmarketresearch
.com Web http//